Oruka Therapeutics (ORKA) Accumulated Expenses (2010 - 2026)
Oruka Therapeutics (ORKA) posted quarterly Accumulated Expenses of $9.3 million for Q1 2026, up 63.99% year-over-year from $5.7 million in Q1 2025, and up 76.36% quarter-over-quarter from $5.3 million in Q4 2025.
Oruka Therapeutics (ORKA) Accumulated Expenses (2010 - 2026) Analysis & Trends
Oruka Therapeutics' Accumulated Expenses history runs 17 years deep, the most recent figure standing at $9.3 million for Q1 2026.
- In Q1 2026, Accumulated Expenses rose 63.99% year-over-year to $9.3 million; the TTM figure through Mar 2026 stood at $9.3 million (up 63.99% YoY), while the FY2025 annual figure was $5.3 million, up 158.01% from the prior year.
- Accumulated Expenses for Q1 2026 stood at $9.3 million, up from $5.3 million in the prior quarter.
- The five-year high for Accumulated Expenses was $9.3 million in Q1 2026, with the low at $84000.0 in Q1 2024.
- The 5-year median for Accumulated Expenses is $324000.0 (2022), against an average of $2.2 million.
- The sharpest annual moves came in 2022 and 2025: Accumulated Expenses sank 81.3% in 2022, then jumped 6641.67% in 2025.
- Oruka Therapeutics' Accumulated Expenses stood at $173000.0 in 2022, then plunged by 42.2% to $100000.0 in 2023, then soared by 1941.0% to $2.0 million in 2024, then jumped by 158.01% to $5.3 million in 2025, then surged by 76.36% to $9.3 million in 2026.
- Business Quant data shows ORKA's Accumulated Expenses at $9.3 million in Q1 2026, $5.3 million in Q4 2025, and $8.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Oruka Therapeutics | 6.98 Bn | 5.25 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.35 Mn |
| Mar 31, 2026 | 9.29 Mn |
| Dec 31, 2025 | 5.27 Mn |
| Sep 30, 2025 | 8.65 Mn |
| Jun 30, 2025 | 3.58 Mn |
| Mar 31, 2025 | 5.66 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 933,000.00 |
| Jun 30, 2024 | 109,000.00 |
| Mar 31, 2024 | 84,000.00 |
| Dec 31, 2023 | 100,000.00 |
| Sep 30, 2023 | 88,000.00 |
| Jun 30, 2023 | 190,000.00 |
| Mar 31, 2023 | 235,000.00 |
| Dec 31, 2022 | 173,000.00 |
| Sep 30, 2022 | 333,000.00 |
| Jun 30, 2022 | 324,000.00 |
| Mar 31, 2022 | 168,000.00 |
| Dec 31, 2021 | 925,000.00 |
| Sep 30, 2021 | 146,000.00 |